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Abstract
The incidence of colorectal cancer (CRC) increases with age and early onset indicates an increased likelihood for genetic
predisposition for this disease. The somatic genetics of tumor development in relation to patient age remains mostly
unknown. We have examined the mutation status of five known cancer critical genes in relation to age at diagnosis, and
compared the genomic complexity of tumors from young patients without known CRC syndromes with those from elderly
patients. Among 181 CRC patients, stratified by microsatellite instability status, DNA sequence changes were identified in
KRAS (32%), BRAF (16%), PIK3CA (4%), PTEN (14%) and TP53 (51%). In patients younger than 50 years (n=45), PIK3CA
mutations were not observed and TP53 mutations were more frequent than in the older age groups. The total gene
mutation index was lowest in tumors from the youngest patients. In contrast, the genome complexity, assessed as copy
number aberrations, was highest in tumors from the youngest patients. A comparable number of tumors from young (,50
years) and old patients (.70 years) was quadruple negative for the four predictive gene markers (KRAS-BRAF-PIK3CA-PTEN);
however, 16% of young versus only 1% of the old patients had tumor mutations in PTEN/PIK3CA exclusively. This implies
that mutation testing for prediction of EGFR treatment response may be restricted to KRAS and BRAF in elderly (.70 years)
patients. Distinct genetic differences found in tumors from young and elderly patients, whom are comparable for known
clinical and pathological variables, indicate that young patients have a different genetic risk profile for CRC development
than older patients.
Citation: Berg M, Danielsen SA, Ahlquist T, Merok MA, A ˚gesen TH, et al. (2010) DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-
PIK3CA-PTEN-TP53 Related to Age at Disease Onset. PLoS ONE 5(11): e13978. doi:10.1371/journal.pone.0013978
Editor: Kelvin Yuen Kwong Chan, The University of Hong Kong, China
Received June 21, 2010; Accepted October 14, 2010; Published November 12, 2010
Copyright:  2010 Berg et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by grants from the Norwegian Cancer Society (http://www.kreftforeningen.no/english) to R.A.L. (grant number 95068/RAL,
including PhD grants to S.A.D., M.B. and T.H.A., and Post doc grant to T.A.), and grants from the Norwegian Foundation for Health and Rehabilitation (http://www.
helseogrehab.no/) through the EXTRA funds (grant number HF-52015/002) to E.T.E. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ragnhild.a.lothe@rr-research.no
Introduction
The incidence of colorectal cancer (CRC, MIM#114500) has
increased in the western world including Norway during the last
50 years [1]. CRC is typically found in elderly people with a
median age at onset of 70 years, and only about five percent of all
cases are diagnosed in patients younger than 50 years of age.
Hereditary syndromes such as familial adenomatous polyposis
(FAP, MIM#175100) and Lynch syndrome (HNPCC, MIM#120435)
are found in less than five percent of all CRCs [2]. Although
early onset of disease is generally accepted to be indicative of a
potential genetic risk, most young at onset cases are regarded as
sporadic as no known genetic predisposition is found [3]. Few
studies have focused on the somatic tumor development in
young patients with no known inherited syndromes [4–6].
Receptor tyrosine kinase (RTK) signaling is essential for
maintaining the metabolism, proliferation, survival and motility
of a cell [7]. Thus, errors in components regulated by receptor
tyrosine kinases (RTKs) are commonly observed in human cancers
[8,9]. The oncogenes KRAS (HGNC:6407), BRAF (HGNC:1097),
and PIK3CA (HGNC:8975) and the tumor suppressor gene PTEN
(HGNC:9588) are all affected in response to cytokines, growth
factors and hormones signaling through RTK.
Both KRAS and BRAF have been shown to have activating
mutations in ,70% of CRCs [10], leading to autonomous ERK-
signaling [11,12]. Mutations in components in the PI3-kinase
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13978pathway have been reported as mutated in ,40% in CRC [13],
and analyses of the genomic landscape of CRC tumors have
shown the PI3K pathway to be affected in a statistically
significantly manner [14]. In two of these components, PTEN
and PIK3CA, mutations result in constitutive activation of the
PI3K pathway by accumulation of phosphatidylinositol (3,4,5)
triphosphate (PIP3), which then catalyzes the phosphorylation of
AKT. The activated serine-threonine kinase AKT regulates a
broad range of target proteins involved in a variety of downstream
signaling pathways [15]. Among AKTs downstream targets is the
tumor suppressor gene TP53 (HGNC:11998), a transcription
factor that integrates information from many different types of
cellular stress, and execute downstream responses appropriate for
the given input [16]. TP53 is found mutated in about half of all
colorectal carcinomas [17].
MSI status in the primary tumor has prognostic impact in CRC
patients [18–20]. KRAS and TP53 status has been associated with
clinical end points, the former only with weak association in larger
series and the latter only if subgroups of mutations are considered
[21–23]. Recently, one study has shown that PIK3CA mutations
may carry prognostic information in tumor stages I–III [24]. This
type of information has not been published for PTEN mutations.
The metastatic disease treatment targeting EGFR is found to be
efficient only if KRAS and BRAF are not mutated [25]. However,
even among the patients with wild type KRAS and BRAF not all
respondtothistherapy[26,26].Lately,ithasbeenproposedthatthis
may be due to mutations in PIK3CA and PTEN, i.e. only quadruple
mutation negative tumors will respond to treatment [26–29].
In the present study we have compared the DNA sequence
mutation status of the genes KRAS, BRAF, PIK3CA, PTEN, and
TP53 in tumor samples from patients younger than 50 years at
diagnosis and without known hereditary syndromes, and stratified
according to MSI status and elderly CRC patients.
Results
Clinicopathological data for the whole series (n=181), divided
into three age groups, are presented in Table 1.
Microsatellite instability- and gene mutation status
The MSI- and mutation-frequencies of the analyzed genes are
presented in Table 1, and a heat map representing mutation data
for all samples is shown in Figure 1. In the total series, MSI was
found in 18% of the samples, ranging from 13% in the ,50 age
group to 20% in the .70 age group. MSI was significantly
associated with localized disease, Table S1. The genes were
mutated within the expected range of frequencies. Mutation
frequencies for each gene independently, and frequencies of
combinations of mutations in the genes tested, were equally
distributed between all stages. Differences attributed to age at
onset are pointed out below.
In total, nine different mutations were observed in KRAS,a f f e c t i n g
codons 12, 13 and 61. Twenty-eight tumors had the BRAF V600E
change. Eight PIK3CA mutations were identified in exons nine and
twenty. Fourteen and fifteen tumors had PTEN mutations and
deletions, respectively. Ninety-three tumors had TP53 mutations.
Details of all mutations observed, can be found in Table S2.
Comparison of age groups
The relationships between the clinical and mutational param-
eters within each age group are given in Table S1. For all age
groups, MSI-tumors were most frequently present in right-sided
tumor localization. In the oldest patient group MSI and BRAF
mutations were statistically significantly correlated (P,0.001). No
such correlation was found in the ,50 age group. The MSI
tumors within the ,50 age group, the 51–70 age group and the
.70 age group had 17%, 54% and 79% BRAF mutations,
Table 1. Clinicopathological features and gene mutation status of colorectal carcinomas for each of the three age groups.
,50 years,
n=45 (%)
51–70 years,
n=67 (%)
.70 years,
n=69 (%)
Age at onset of disease Min 27 51 71
Max 50 70 93
Mean 41 61 80
Sex Female 23 (51) 31 (46) 36 (52)
Male 22 (49) 36 (54) 33 (48)
Tumor location in the large bowel Right 12 (27) 29 (43) 33 (48)
Left 16 (36) 15 (22) 20 (29)
Rectum 17 (38) 23 (34) 16 (23)
Stage I 5 (11) 14 (21) 16 (23)
II 16 (36) 22 (33) 28 (41)
III 17 (38) 22 (33) 22 (32)
IV 7 (16) 9 (13) 3 (4)
Mutations
1 KRAS 13 (30) 20 (30) 24 (35)
BRAF 3 (7) 12 (18) 13 (19)
PIK3CA 0 5 (8) 3 (4)
PTEN* 8 (18) 7 (10) 11 (16)
TP53 29 (64) 26 (39) 38 (55)
MSI 6 (13) 13 (19) 14 (20)
*Impaired PTEN: Combined results from sequencing and MLPA.
1Percentages are calculated based on the number of patients with successful analyses.
doi:10.1371/journal.pone.0013978.t001
Mutations in Colorectal Cancer
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the ,50 group only half of the samples carried mutations in the
genes analyzed, whereas among MSI tumors in the other two age
groups, all samples displayed one or several mutations.
KRAS mutations were found in 57 (32%) tumors in the total
series. The mutation frequencies were slightly different between
the age groups, Table 1. Most of the mutations were found in
codons 12 (68%) and 13 (28%) independent of age group. The
codon 61 mutations were only found in samples from the .70 age
group.
KRAS and BRAF mutations were mutually exclusive in the total
series. The frequency of tumor mutations in either KRAS or BRAF
increased with patient age, both when comparing age groups and
with age as a continuous variable.
Surprisingly, none of the tumors in the ,50 age group had
PIK3CA mutations, whereas five (7%) and three (4%) were found
in the 51–70 group and .70 group, respectively.
Eighteen PTEN mutations were identified in seven of nine exons
(no mutations were observed in exon 4 and 9). The mutations were
observed in all age groups, as was the case for PTEN deletions.
Deletions detected by MLPA were found in eight percent of the
samples in total, and coexistence of deletion and alterations
detected by sequencing were found in three tumors. Overall, 14%
of the tumors had indication of impaired PTEN function. The
frequency of PTEN aberrations showed no statistically significant
difference between the age groups; 18%, 10% and 16% in ,50
group, 51–70 group and .70 group, respectively.
The number of TP53 mutated tumors differed among the three
age groups (P=0.02). This difference was also significant when
analyzing MSS tumors only, (P=0.03). Mutations were most
prominent in the DNA binding domain, encoded by exons 5–8,
and only about five percent of the mutations were observed in
exon 4 and exon 11. Moreover, in the ,50 age group, TP53
mutations and MSI were mutually exclusive, and inversely
correlated in the 51–70 and .70 groups, respectively.
Genome complexity and sequence mutations
For a subset of the samples (n=41) a high resolution dataset of
copy number changes obtained by array comparative genome
hybridization data (aCGH) was available (Roche NimbleGen,
385 000 oligo probe array) [30]. As previously published [30], we
found the ,50 group to have a significantly greater number of
aberrations than the .70 group, even though the total portion of the
genome with aberrations was similar in the two groups, Table 2. A
difference in complexity was also found at the gene level, assessed as
mutation index: in the older group each patient had 1.5 mutations on
average, compared to 1.0 in the younger age group. The distribution
of tumor stages was somewhat skewed between the two groups.
However, neither the percentage of genomic aberrations, nor
number of mutations differed among the tumor stages.
Clinical associations
No difference in survival was found comparing the age groups,
even when adjusting for tumor stage at diagnosis. There was a
trend that the proportion of rectal tumors decreased with
increasing age (P=0.08), and the younger patients tended to have
a more advanced tumor stage than elderly patients. The
prevalence of stage III–IV tumors was 54%, 46%, and 36% in
the ,50, 51–70 and .70 groups, respectively.
In the total sample set, tumor stage was the most powerful
prognostic variable with regard to three-year overall survival,
(P,0.001). In univariate analysis, patients with TP53 mutated
tumors had poorer survival rates than patients with wild-type
TP53, 938631 days vs. 1016623 days (P=0.04), respectively.
However this difference was not significant when correcting for
tumor stage. TP53 mutations were of higher prognostic signifi-
cance in right-sided tumors, 1051626 days vs. 8836 65 days for
wild type and mutated TP53, respectively (P=0.005).
Among patients in the youngest age group, those with KRAS
mutation had significantly shorter survival than patients with
KRAS wild-type samples, 8416101 days vs. 1033635 days
(P=0.02), respectively. None of the other mutational parameters
showed any statistically significant difference with regard to
survival, neither within nor between age groups.
Discussion
We found that the mutation status of a known cancer gene set
varies in CRC patients depending on age at onset of disease, and
Figure 1. Mutation pattern within age groups. Distribution of mutations in the gene set KRAS-BRAF-PIK3CA-PTEN-TP53, and MSI status, within
each age group. Color coding: dark blue = MSI, light blue = MSS, red = mutation, green = wild type, white = not detected.
doi:10.1371/journal.pone.0013978.g001
Table 2. Gene mutation index and genomic complexity in young and elderly CRC patients.
Onset ,50 years,
n=24
Onset .70 years,
n=17 P-values
Mean number of mutations per patient 1.04 1.47 0.14
Median number of regions with copy number aberration per patient 43.29 26.88 0.02
Median percentage of normal copy number per patient 71.72 77.23 0.66
Median number of mutations per patient (=gene mutation index) is based on data from analyses of KRAS, BRAF, PIK3CA, PTEN and TP53. Median number of regions with
copy number aberrations (=genomic complexity) and median percentage of normal copy number per patient are based on results from aCGH analysis.
doi:10.1371/journal.pone.0013978.t002
Mutations in Colorectal Cancer
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of tumors in young and elderly patients.
Microsatellite instability status
In all age groups, MSI was statistically significantly associated with
right-sided tumors, as expected [18,18,31,32]. The frequency of MSI
in the present series was somewhat higher than reported elsewhere
[33,34], which is best explained by a random excess of right-sided
tumors in the total series. However, for the group of patients younger
than 50 years at diagnosis the frequency observed were slightly lower
than expected [33], which partly could be explained by the exclusion
of patients with known CRC syndromes in this study.
In patients younger than 50 years only 50% of the MSI samples
were mutated in one or more of the genes analyzed, whereas in
patients older than 50 all MSI samples displayed gene alterations.
Additionally, BRAF mutations were not statistically significantly
associated with MSI in the ,50 years group, contrary to what was
expected [35]. The mutation in BRAF
V600E is observed to induce
down-regulation of essential DNA repair genes [36], with potential
to induce MSI in the cell, explaining this correlation. As BRAF
mutations are not observed in tumors from patients with Lynch
syndrome [37], we cannot exclude that MSI/BRAF wild-type
samples in the present series are from clinically undetected Lynch
syndrome patients.
Gene mutations
Mutations frequencies in KRAS, BRAF, PIK3CA, PTEN, and
TP53 were found to be within previously reported range
supporting the representativeness of the series [38].
The coexistence of BRAF and KRAS mutations is presumed to
be incompatible with proliferation, hence a negative selection for
concurrent existence of both mutations [12]. We did confirm an
inverse correlation between mutations of these two genes [39]. In
addition, an increasing number of tumors with either KRAS or
BRAF mutation was observed with increasing age, in agreement
with a recent report on young patients with colorectal cancer [6].
In the total series, tumors displaying BRAF
V600E were typically
TP53 wild type and PTEN mutated (Table S1), which was also the
case for tumors within the .70 age group. Thus, ‘‘BRAF
V600E,
TP53wt, PTENmut’’ may be regarded as a feature of genuine
sporadic tumors.
In comparison to the reported 14% frequency of PIK3CA
mutations in colorectal carcinomas in the COSMIC database
[38], the current series shows only 4% mutations. This may partly
be explained by the fact that the current series is enriched with
samples from young patients, and their tumors did not have
PIK3CA mutations. However, this latter observation is in contrast
with two previous studies [6,40] that reports two/one patients
younger than 50 years with PIK3CA mutations. The different
methodologies used, sample type, formalin-fixed or fresh frozen
tissue, and the size of the series may partly explain this difference
in mutation frequency among the studies. Mutation in either the
oncogene PIK3CA or the tumor suppressor gene PTEN may lead to
an accumulation of PIP3, and downstream AKT activation.
However, since a sequence change in PTEN imply one remaining
wild type allele, additional activating mutation in the same
pathway may be beneficial for the tumor cells [41]. We found 32
tumors with alteration(s) in each of PIK3CA and/or PTEN,
including seven tumors with several PTEN aberrations. The whole
coding sequence of PTEN has been explored [42–48], but none of
the studies have investigated tumors from young patients
specifically. To our knowledge this is the first report combining
PTEN whole coding sequence data with the gross deletion pattern
in CRC from different age groups.
The TP53 mutation frequency was significantly higher in the
,50 age group, than in the other age groups, which is best
explained by the higher frequency of left sided and rectal cancers
in the ,50 age group. As expected, TP53 mutations were
associated with MSS tumors, and the significant difference
between the age groups was still valid when analyzing MSS
tumors only.
A mutation index was calculated and tumors from elderly
patients were found to have accumulated more gene sequence
changes than the ones from young patients (1.5 vs. 1.0) which
might indicate a time difference in tumor development.
Distinct genetic make-up of tumors from young and
elderly patients
From aCGH data on a subset of 41 samples, we observed that
patients younger than 50 years had significantly more aberrations
in their tumors than patients .70 years did, i.e. a higher degree of
genomic complexity. Contrary, as mentioned above, the tumors
from elderly patients had the highest gene mutation index, even
though this group included fewer advanced stages. Taken
together, one may speculate that among the young patients there
are carriers with genetic predisposition affecting genes encoding
proteins that ensure correct chromosome segregation during
mitosis, rather than specific pathways.
Bardelli et al. [29] reported that patients with metastatic disease
that are ‘‘quadruple negative’’ in the KRAS-BRAF-PIK3CA-PTEN
gene set have the highest probability of response to anti-EGFR
therapies. However, currently only KRAS testing is recommended
prior to decision with regard to such treatment, and BRAF testing
is optional [49].
In the present series of primary cancers, mutation frequencies in
these four genes were equally distributed between all tumor stages.
Therefore, we have in the following hypothesized the number of
potential responders based on the whole dataset (Figure 2). When
considering tumors with impaired PTEN and/or mutated PIK3CA
exclusively, the youngest age group displayed 16% (n=7)
mutations, compared to 1.4% (n=1) in the oldest age group.
This implies that for older patients, KRAS and BRAF mutation
status alone will reveal 98% of the patients unsuitable for anti-
EGFR therapy, as compared to 71% in patients ,50 years. The
effect of mutations in PIK3CA and PTEN are debated with regard
to anti-EGFR therapy [26,28,29]. Notwithstanding, if their
mutational status does not influence on the effect of anti-EGFR
treatment, the younger patients will be expected to have an even
larger proportion of potential responders to this type of treatment
than the older patients (Figure 2).
Association to clinical data
The consecutive sample series of colorectal carcinomas from a
single hospital showed overall distribution of clinicopathological
data as expected for a Norwegian cohort [1]. The proportion of
rectal cancers decreased with increasing age at onset, whereas the
opposite trend was seen forright-sided tumors, asreported byothers
[50,51]. Furthermore, a larger part of the patients diagnosed before
age 50 years had more advanced disease stage compared to the
older age groups. Thismayreflectthat CRCis unexpected in young
adults and symptoms are neglected both by the patient and the
physician [52]. Reports of young colorectal cancer patients differs
with regards to aggressiveness of the disease, and hence outcome
[3,52,53]. However, in the present study, the three-year overall
survival was equal in the three age groups, even when adjusting for
tumor stage. This might indicate a more aggressive disease in young
patients, as older people are expected to have a higher mortality
rate. Furthermore, the observed higher degree of genomic
Mutations in Colorectal Cancer
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indicative of a difference in aggressiveness. It should be noted, that
the young patients included are not carriers of known colorectal
cancer syndromes according to clinical criteria only.
The prognostic and predictive value of TP53 is still controversial
[54]. In our dataset patients with TP53 mutations had significantly
shorter survival than wild type patients. Furthermore, for patients
with right-sided or MSI tumors TP53 mutations showed even
greater prognostic value, in line with results reported by the TP53-
CRC collaborative study group [55].
In a recent study, PIK3CA mutations were found to serve as
surrogate markers for poor survival in colorectal cancer patients
[24]. As few PIK3CA mutations were observed in our sample set,
we could not confirm these results. However, mutations were
found only in samples from older patients, and were not present in
patients with distant metastases, and only few in stage III patients.
Thus, our data suggest that PIK3CA mutations are important for
tumorigenesis among elderly patients, but do not serve as a marker
for the ability to metastasize.
Conclusion
We have found distinct differences in the genetic make-up of
carcinomas from young and elderly patients. The tumors from
young patients whom are not carriers of known hereditary CRC
syndromes have less gene mutations, but more copy number
aberrations across the genome. These data suggest that some
young patients may have a potential increased risk for cancer
caused by alterations in gene(s) involved in maintaining correct
chromosome segregation.
Materials and Methods
Ethics statement
Written informed consent was obtained from all subjects
included. The research biobanks are registered according to
national legislation and the research studies are approved by the
Regional Committee for Medical Research Ethics (REK South-
East: 1.2005.1629; REK South, 2003: S-02126).
Patients and tumor samples
A total of 181 patients were included in the study, i.e. a
consecutive series of 132 patients enriched with a series of 49
patients with disease at young age (,50 years). Each series are
described in the following paragraphs. Clinical data were collected
prospectively. Death data were retrieved from either the hospital
records or from the Norwegian Population Registry. The clinical
and pathological data of these two series are shown in Table S3.
Figure 2. Graphic representation of patients with hypothesized response to EGFR-targeted therapy. Percent-wise distribution of
aberrations for KRAS, BRAF, PIK3CA and PTEN and their combinations, in the ,50 age group and .70 age group. Patients negative for all mutations
(quadruple negative) are potential responders to anti-EGFR-therapy. (Modified from Bardelli et al.[29])
doi:10.1371/journal.pone.0013978.g002
Mutations in Colorectal Cancer
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resection of colorectal adenocarcinoma in 2005–2007 at Oslo
University Hospital, Aker, Oslo, were included. Patients with FAP-
or Lynch syndrome were excluded based on clinical criteria.
Tumor tissue was sampled immediately after resection of the
specimen and instantly frozen in liquid nitrogen. All tissue
specimens were evaluated by a pathologist to establish differen-
tiation grade of the carcinoma and tumor cell content.
Early onset series (n=49). Samples from a biobank from a
multi-hospital study (INFAC-study - individuals with familial risk
for cancer), including Oslo University Hospital, Aker, Oslo and
five other hospitals in the same geographical region of Norway
enrolled from 2003–2008, were included in the present study. The
inclusion criteria in the INFAC-study were age ,55 years,
excluding those who fulfilled criteria of all known CRC
syndromes. Tumor tissue and corresponding normal mucosa
samples were taken from the resected specimen in the operation
theatre and promptly incubated in RNAlater. The tissue was
transferred to new tubes after 36–72 hours, and stored at minus
80uC until use. DNA from normal and cancerous tissues was
extracted, and used for analysis.
Samples included in CGH analysis. For a subset of the
patients (n=41) data from aCGH analyses were available. This
subset included 24 patients younger than 50 years, and 17 older
than 70 years at primary diagnosis. Clinical and mutational data
for these patients are presented in Table S2.
Grouping of patients according to age. Patients from the
early onset series were included to enrich the number of early
onset patients in the total sample set. Patients from the early onset
series were selected to match patients younger than 55 years in the
consecutive series with regard to gender, median age, tumor stage
and localization, Table S3. Thereafter, samples from the two series
were combined and divided into three age groups; under age 50
years, 51 through 70 years and over 70 years, referred to as ,50,
51–70 and .70, respectively. The mean age at primary diagnosis
was 70 years in the consecutive series, and that was chosen as
cutoff for the oldest age group. The cutoff for the youngest age
group was set at 50 years, since early onset may be due to inherited
genetic factors, and only ,5% of all CRC are diagnosed before 50
years of age. Tumors in the colon proximal to the splenic flexure
were defined as right-sided: those in the remaining colon were
regarded as left-sided whereas rectum was defined as 15 cm from
the anal verge when measured with a rigid proctoscope. Localized
disease was defined for UICC/AJCC stages I and II and regional
disease for stages III and IV.
Microsatellite instability analysis
For all patients, tumor and corresponding normal tissue or
blood was analyzed using the Bethesda markers [56]. The analysis
was performed as described by Wu et al.[57]. High degree of
microsatellite instability (MSI-H) in tumor DNA, as compared to
corresponding normal DNA, was defined if two or more markers
showed aberrant peak profile after fragment analysis. If both the
normal sample and the tumor sample from a patient showed the
same pattern for all markers, the tumor was regarded microsat-
ellite stable (MSS).
Mutation analysis for KRAS, BRAF, PIK3CA, PTEN and TP53
For BRAF and KRAS, activating mutations at positions known to
frequently carry alterations are reported [11,58]. In the PIK3CA
gene mutations in colorectal cancers cluster in exons 9 and 20
[59], and for TP53 and PTEN mutations are reported throughout
the whole coding sequence [17,60].
For TP53 and PTEN, the total coding sequence was amplified in
multiplex PCR reactions, using multiplex PCR kit as recommend-
ed by the vendor (QIAGEN, GmBH, Hilden, Germany) [30,60].
Singleplex PCR reactions using HotStar Taq (QIAGEN) were
used to amplify PIK3CA, KRAS and BRAF amplicons [10,59,61]. In
PIK3CA exons 9 and 20 were amplified, in KRAS, exons 2 and 3,
including the frequently mutated codons 12, 13 and 61, and in
BRAF exon 15, including the mutation in codon 600, were
amplified. Primers, running conditions and fragment details are
described in Table S4.
PCR products were purified using Sephadex columns (Milli-
pore, Billerica, MA, US and GE Healthcare, Chalfont St.Giles,
UK) prior to incorporation of dye labeled ddNTP’s and
sequencing on the 3730 DNA Analyzer (Applied Biosystems,
Foster City, CA, US) [30]. In cases where a mutation was
detected, a new independent PCR product was subjected to
sequencing to confirm the result.
Multiplex ligation-dependent probe amplification (MLPA)
of PTEN
Salsa MLPA kit P225-B2 PTEN (MRC Holland, Amsterdam,
Netherlands) were used according to instructions from distributor.
In total, 25 probes cover the PTEN gene, a minimum of two
probes for each of the nine exons. Also, 10 probes located
elsewhere on chromosome 10, and additional 12 reference probes
located on other chromosomes serves as controls. Amplified
fragments were analyzed on a 3730 DNA Analyzer (Applied
Biosystems). Raw data were analyzed with CoffalyzerH (MRC
Holland) with default settings. Cutoffs of 1.2 and 0.8 were used for
scoring of gains and losses, respectively, in addition to individual
evaluation of the plot from each sample. This scoring is
determined according to the following calculation: one copy gain
or loss in 60% of the cells in a triploid tumor equals 1.2 and 0.8,
respectively. At least two neighboring probes, located in the same
exon, with concomitant gain or loss, were confined for assigning
aberrant copy number in a region.
Statistical analyses
Clinical variables were tested for associations with mutational
results for all genes analyzed, and all genes were tested for inter-
relational associations. All statistical analyses were performed
using the software package PASW 17.0 (SPSS Inc., Chicago, IL,
US). Fisher’s exact test was used for cross-tabulated variables.
Student T-test was performed when calculating the relationship
between a continuous variable and a categorical variable. Survival
analyses were performed using the Kaplan–Meier life table
analyses with three years overall survival, and log rank test used
to compare the survival curves. For all statistical tests, a two-tailed
P,0.05 was considered significant.
Supporting Information
Table S1 Relation of mutational and clinical data on tumors
from included patients. NS=not significant, NA=not applicable.
All P-values ,0.20 are shown in the table, and P,0.05 is high-
lighted in bold.
Found at: doi:10.1371/journal.pone.0013978.s001 (0.03 MB
XLS)
Table S2 Details of clinical and mutational data from KRAS,
BRAF, PIK3CA, PTEN and TP53. * F=female, M=male. #
patients included in Table 2. 1 results from MLPA.
Found at: doi:10.1371/journal.pone.0013978.s002 (0.05 MB
)
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XLSTable S3 Clinical characteristics in different age groups.
Distribution of clinical data in the total consecutive series, young
in consecutive series (patients under age 55 years), early onset
series (,55 years), and in the total series of patients.
Found at: doi:10.1371/journal.pone.0013978.s003 (0.03 MB
XLS)
Table S4 PCR and primer details for genes analyzed. *M13
forward primer (TGTAAAACGACGGCCAGT). #M13 reverse
primer (CAGGAAACAGCTATGACC).
Found at: doi:10.1371/journal.pone.0013978.s004 (0.03 MB
XLS)
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